Study of CD19 chimeric antigen receptor T cells in Induction Therapy in Lymphoma-associated HLH

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100044617

Enrollment

Unknown

Registered

2021-03-24

Start date

2021-07-01

Completion date

Unknown

Last updated

2021-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma-associated HLH

Interventions

CART Group:CDl9 CAR-T cell therapy

Eligibility

Sex/Gender

All

Age

5 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. CD19-positive B cel-NHL patients were confirmed by pathology and immunohistochemistry; 2. Aged from 5 to 70 years; 3. Estimated life expectancy more than 12 weeks; 4. Adequate venous access. 5. Physical score > 50 (Karnofsky PerformanceStatus); 6. Normal liver, kidney, and cardiac function.

Exclusion criteria

Exclusion criteria: 1. With a serious autoimmune disease or other tumor disease; 2. With systemic or local uncontrollable infection; 3. With active hepatitis B and C infection; 4. With HIV infection; 5. With psychiatric disorders.

Design outcomes

Primary

Measure	Time frame
over survival;progression-free survival;	—

Secondary

Measure	Time frame
overall response ratio;complete remission rate;partial response rate;disease free survival;	—

Countries

China

Contacts

Public ContactZhou Yulan

The First Affiliated Hospital of Nanchang University

wenxin_yl@163.com+86 18770049831

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026